Log In
BCIQ
Print this Print this
 

ALZT-OP1

  Manage Alerts
Collapse Summary General Information
Company AZTherapies Inc.
DescriptionTherapy comprising inhaled cromolyn (ALZT-OP1a), a beta amyloid polymerization inhibitor, and oral ibuprofen (ALZT-OP1b), an NSAID
Molecular Target Beta amyloid ; Cyclooxygenases (COX)
Mechanism of ActionCyclooxygenase (COX) inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase III
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat early stage Alzheimer's disease (AD)
Regulatory Designation U.S. - Special Protocol Assessment (Treat early stage Alzheimer's disease (AD))
PartnerMassachusetts General Hospital

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today